Hematology: Bortezomib in newly diagnosed multiple myeloma.
Preclinical studies have shown that new agents such as bortezomib not only demonstrate anti-multiple-myeloma activity as single agents but also enhance the efficacy of both chemotherapy and steroids. A randomized trial has established that bortezomib not only improves response rates but also prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy.
Berenson
James R
JR
Institute for Myeloma and Bone Cancer Research, West Hollywood, CA 90069, USA. jberenson@myelomasource.org
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D008558:Melphalan; D011241:Prednisone